Caribou is halting vispa-cel and CB-011, allogeneic CAR-T therapies that showed up to 92% response rates, citing a difficult financing environment.
News|Articles|March 31, 2026
Strategic Alliances in Bioprocessing and R&D: A Q&A with Dr. Manisha Desai of Bristol Myers Squibb
Author(s)Feliza Mirasol, Manisha P. Desai
Bristol Myers Squibb’s Dr. Manisha Desai, senior vice president of Product Development, notes how strategic bioprocessing alliances accelerate drug development by integrating R&D and manufacturing to scale complex biologics and ensure reliability.
Advertisement
Advertisement
Strategic partnerships have become a cornerstone of modern drug development, driving innovation across increasingly complex therapeutic landscapes. BioPharm International® discussed how these alliances are reshaping bioprocessing, biopharma R&D, and manufacturing workflows with
Related to this article
CSL and Alentis will co-develop lixudebart, an antibody targeting claudin-1, across 3 rare kidney and liver disease indications.
AL050 aims to treat GBA1-driven Parkinson disease by delivering a GCase enzyme across the blood-brain barrier.
Novartis has secured an exclusive worldwide license to ABO2203, Abogen's investigational mRNA-encoded CD19xCD3 T-cell engager designed to produce the bispecific inside the body to reset B cells in autoimmune disease. The agreement also includes options on other programs built on Abogen's RNA platform.
The 15-month project could let living cell therapies ship and store at room temperature, cutting cold-chain costs that limit patient access.
A planned phase 3 trial will test the TROP2 ADC and PD-1/VEGF bispecific together in 1st-line triple-negative breast cancer.
Sanofi is paying Regeneron up to $8 billion to co-develop REGN20423 and 3 other long-acting antibodies beyond dupilumab (Dupixent).
Antisense oligonucleotides are reshaping drug design, from RNase H gapmers to inhaled delivery; this FAQ explains how they work and why trials still fail.
Advertisement
Advertisement